Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
CONTACT<br />
Dr Johanna Holldack, MD<br />
Chief Executive Officer<br />
ADDRESS<br />
TELORMEDIX SA<br />
Via della Posta 10<br />
CH-6934 Bioggio<br />
Switzerland<br />
TELEPHONE<br />
+41 (0)91 610 7000<br />
FAX<br />
+41 (0)91 610 7031<br />
EMAIL<br />
Telormedix@telormedix.com<br />
YEAR FOUNDED<br />
2007<br />
Telormedix<br />
www.telomedix.com<br />
COMPANY PROFILE<br />
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune<br />
system in treating autoimmune diseases and cancer. Telormedix is particularly interested in the role of Toll-like<br />
Receptor 7 (TLR7) for the topical treatment of cancer.<br />
The Company’s lead product, TMX-101, is currently in a Phase I/II clinical trial for the treatment of Non-<br />
Muscle Invasive Bladder Cancer (NMIBC) and has showed a good safety profile in humans. TMX-101 is a new<br />
formulation of a clinically-active small molecule compound with a known and favourable safety profile and a<br />
specific immunotherapeutic target. Telormedix has optimized TMX-101 specifically for the localised treatment of<br />
bladder cancer, the fifth most prevalent cancer and a disease of significant unmet medical need. TMX-101 will<br />
be the first targeted therapy dedicated to bladder cancer and the first to modulate the innate immune system for<br />
this indication.<br />
The second product, TMX-202, is a small molecule for the topical treatment of skin and bladder cancers that<br />
has already provided significant preclinical results. Within the TMX-20X series, the Company also has another<br />
product called TMX-201, which is being developed for use as a vaccine adjuvant. Proof of concept has recently<br />
been established in relevant animal models. An additional product, TMX-302, is part of a pipeline programme<br />
targeting autoimmune diseases.<br />
MANAGEMENT<br />
Johanna Holldack, MD, CEO<br />
Roberto Maj, PharmD, Founder/Head of Drug Development<br />
Alcide Barberis, PhD, Head of Research and Collaborations<br />
Filippo Riva, MBA, CFO<br />
Raffaella Pozzi, PharmD, Head of Clinical Operations<br />
Nadia Passini, PhD, Project Management Director<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS